Revisão Acesso aberto

Antipsychotic dose reduction compared to dose continuation for people with schizophrenia

2022; Elsevier BV; Volume: 2022; Issue: 11 Linguagem: Inglês

10.1002/14651858.cd014384.pub2

ISSN

1465-1858

Autores

Alessandro Rodolico, Spyridon Siafis, Irene Bighelli, Myrto Samara, Wulf‐Peter Hansen, Salvatore Salomone, Eugenio Aguglia, Pierfelice Cutrufelli, Ingrid Bauer, Lio Baeckers, Stefan Leucht,

Tópico(s)

Health Systems, Economic Evaluations, Quality of Life

Resumo

Antipsychotic drugs are the mainstay treatment for schizophrenia, yet they are associated with diverse and potentially dose-related side effects which can reduce quality of life. For this reason, the lowest possible doses of antipsychotics are generally recommended, but higher doses are often used in clinical practice. It is still unclear if and how antipsychotic doses could be reduced safely in order to minimise the adverse-effect burden without increasing the risk of relapse.

Referência(s)